A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCTID	NCT06164730 (View at clinicaltrials.gov)
Description	VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population. (Show More)
Development Status	Active
Indication	Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Disease Ontology Term	DOID:13810
Compound Name	VERVE-102
Sponsor	Verve Therapeutics, Inc.
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	36
Results Posted	Not Available

No.of Trial Sites	8
Locations	New Zealand,Canada,United Kingdom,Australia

Has US IND	True
FDA Designations
Recent Updates	Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025; Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort; IND cleared by FDA in March 2025